Meeting
2021 ASCO Annual Meeting
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).
Authors
Michael B. Atkins
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Michael B. Atkins , Opeyemi Jegede , Naomi B. Haas , David F. McDermott , Mehmet Asim Bilen , Jessica Hawley , Jeffrey A. Sosman , Robert S. Alter , Elizabeth R. Plimack , Moshe Chaim Ornstein , Michael E. Hurwitz , David J. Peace , Sabina Signoretti , Catherine J. Wu , Paul J. Catalano , Hans J. Hammers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03117309
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4510)
DOI
10.1200/JCO.2021.39.15_suppl.4510
Abstract #
4510
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
First Author: Michael B. Atkins
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2020 ASCO Virtual Scientific Program
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.
First Author: Bradley Alexander McGregor
Poster
2019 ASCO Annual Meeting
Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).
First Author: Bradley Alexander McGregor